These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30858110)

  • 1. Reversal of a Treatment-Resistant, Depression-Related Brain State with the Kv7 Channel Opener Retigabine.
    Feng M; Crowley NA; Patel A; Guo Y; Bugni SE; Luscher B
    Neuroscience; 2019 May; 406():109-125. PubMed ID: 30858110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel dual-mechanism Kv7 potassium channel/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model.
    Bloms-Funke P; Bankstahl M; Bankstahl J; Kneip C; Schröder W; Löscher W
    Neuropharmacology; 2022 Feb; 203():108884. PubMed ID: 34785163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anticonvulsant retigabine suppresses neuronal K
    Stas JI; Bocksteins E; Jensen CS; Schmitt N; Snyders DJ
    Sci Rep; 2016 Oct; 6():35080. PubMed ID: 27734968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity.
    Musella S; Carotenuto L; Iraci N; Baroli G; Ciaglia T; Nappi P; Basilicata MG; Salviati E; Barrese V; Vestuto V; Pignataro G; Pepe G; Sommella E; Di Sarno V; Manfra M; Campiglia P; Gomez-Monterrey I; Bertamino A; Taglialatela M; Ostacolo C; Miceli F
    J Med Chem; 2022 Aug; 65(16):11340-11364. PubMed ID: 35972998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
    Gunthorpe MJ; Large CH; Sankar R
    Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder.
    Tan A; Costi S; Morris LS; Van Dam NT; Kautz M; Whitton AE; Friedman AK; Collins KA; Ahle G; Chadha N; Do B; Pizzagalli DA; Iosifescu DV; Nestler EJ; Han MH; Murrough JW
    Mol Psychiatry; 2020 Jun; 25(6):1323-1333. PubMed ID: 30385872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retigabine: chemical synthesis to clinical application.
    Blackburn-Munro G; Dalby-Brown W; Mirza NR; Mikkelsen JD; Blackburn-Munro RE
    CNS Drug Rev; 2005; 11(1):1-20. PubMed ID: 15867950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
    Kalappa BI; Soh H; Duignan KM; Furuya T; Edwards S; Tzingounis AV; Tzounopoulos T
    J Neurosci; 2015 Jun; 35(23):8829-42. PubMed ID: 26063916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retigabine holds KV7 channels open and stabilizes the resting potential.
    Corbin-Leftwich A; Mossadeq SM; Ha J; Ruchala I; Le AH; Villalba-Galea CA
    J Gen Physiol; 2016 Mar; 147(3):229-41. PubMed ID: 26880756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retigabine: the newer potential antiepileptic drug.
    Czuczwar P; Wojtak A; Cioczek-Czuczwar A; Parada-Turska J; Maciejewski R; Czuczwar SJ
    Pharmacol Rep; 2010; 62(2):211-9. PubMed ID: 20508276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pan-Kv7 (KCNQ) Channel Opener Retigabine Inhibits Striatal Excitability by Direct Action on Striatal Neurons In Vivo.
    Hansen HH; Weikop P; Mikkelsen MD; Rode F; Mikkelsen JD
    Basic Clin Pharmacol Toxicol; 2017 Jan; 120(1):46-51. PubMed ID: 27377794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
    Vanhoof-Villalba SL; Gautier NM; Mishra V; Glasscock E
    Epilepsia; 2018 Feb; 59(2):358-368. PubMed ID: 29265344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations.
    Ihara Y; Tomonoh Y; Deshimaru M; Zhang B; Uchida T; Ishii A; Hirose S
    PLoS One; 2016; 11(2):e0150095. PubMed ID: 26910900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional up-regulation of the M-current by retigabine contrasts hyperexcitability and excitotoxicity on rat hypoglossal motoneurons.
    Ghezzi F; Monni L; Nistri A
    J Physiol; 2018 Jul; 596(13):2611-2629. PubMed ID: 29736957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced in vitro CA1 network activity in a sodium channel β1(C121W) subunit model of genetic epilepsy.
    Hatch RJ; Reid CA; Petrou S
    Epilepsia; 2014 Apr; 55(4):601-8. PubMed ID: 24605816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice.
    Hirano K; Kuratani K; Fujiyoshi M; Tashiro N; Hayashi E; Kinoshita M
    Neurosci Lett; 2007 Feb; 413(2):159-62. PubMed ID: 17184917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of K
    Djouhri L; Malki MI; Zeidan A; Nagi K; Smith T
    J Drug Target; 2019 Dec; 27(10):1118-1126. PubMed ID: 30995134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Kv7 potassium channel activator retigabine decreases alcohol consumption in rats.
    Knapp CM; O'Malley M; Datta S; Ciraulo DA
    Am J Drug Alcohol Abuse; 2014 May; 40(3):244-50. PubMed ID: 24735395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retigabine calms seizure-induced behavior following status epilepticus.
    Slomko AM; Naseer Z; Ali SS; Wongvravit JP; Friedman LK
    Epilepsy Behav; 2014 Aug; 37():123-32. PubMed ID: 25016241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures.
    Tompson DJ; Crean CS; Reeve R; Berry NS
    Clin Ther; 2013 Aug; 35(8):1174-1185.e4. PubMed ID: 23916044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.